Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric citrate in pediatric iron deficiency anemia with CKD
NCT04649411Phase 3Withdrawn
- Sponsor
- Keryx Biopharmaceuticals, Inc.
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in iron deficiency anemia (IDA) comparing Ferric citrate with Standard of care (2 arms). Primary endpoints: Treatment-emergent Adverse Events at 28 weeks, Clinically Significant Laboratory Abnormalities at 24 weeks and 1 more. Planned start Jan 2025; status: withdrawn.
02
Drugs
ferric citrate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT04649411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649411.